German restrictions of patient’s access off the table

Bedrocan highly welcomes that drastic restrictions of patient’s access to medical cannabis discussed in Germany are off the table. The German G-BA (Federal Joint Committee, a decision-making body regulating reimbursements for patients with public health insurance in Germany) decided on March 16 to cancel plans to tighten the currently applicable rules for prescribing medical cannabis. According to the original G-BA draft, most doctors could have lost their right to prescribe medical cannabis and health insurances could have refused a larger proportion of prescriptions. As the largest supplier of medical cannabis in the EU and the only purely pharmaceutical market player with an exclusive focus on patients, Bedrocan is pleased with the fact that the initially proposed restrictions are not being implemented.

Jaap Erkelens
Jaap Erkelens

Bedrocan CEO Jaap Erkelens comments: “Our experiences from Canada and the Netherlands show that such restrictions would have led to shortcomings for suffering patients. They would have been forced into the black market and into medically unaccompanied self-medication. We are relieved that decision makers in Germany understand this danger, which increases even further with the planned liberalisation of recreational cannabis. Before that liberalisation, patients’ access to medicinal cannabis should not become more difficult but easier.”

G-BA regulates the prescription of medical cannabis in the case of serious illnesses

No additional requirements that go beyond the legally mandatory prescription requirements that are binding for the G-BA

You can find more details in German on the website of G-BA.

Subscribe to our newsletter

Stay informed with our latest updates by subscribing to our newsletter for exclusive news and compelling content. Rest assured, we prioritize the integrity of your inbox, delivering quality over quantity, with newsletters dispatched judiciously.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.

Start typing and press Enter to search